Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers
Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
3.1. Demographics and Outcome of Women with T1N0M0 Cancers
3.2. Factors Associated with Disease Recurrence
3.3. Recommendation for Chemotherapy
3.4. Chemotherapy Treatment and Outcomes
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bland, K.I.; Menck, H.R.; Scott-Conner, C.E.; Morrow, M.; Winchester, D.J.; Winchester, D.P. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 1998, 83, 1262–1273. [Google Scholar] [CrossRef] [PubMed]
- Berry, D.A.; Cronin, K.A.; Plevritis, S.K.; Fryback, D.G.; Clarke, L.; Zelen, M.; Mandelblatt, J.S.; Yakovlev, A.Y.; Habbema, J.D.; Feuer, E.J.; et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 2005, 353, 1784–1792. [Google Scholar] [CrossRef] [PubMed]
- Vaz-Luis, I.; Ottesen, R.A.; Hughes, M.E.; Mamet, R.; Burstein, H.J.; Edge, S.B.; Gonzalez-Angulo, A.M.; Moy, B.; Rugo, H.S.; Theriault, R.L.; et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. J. Clin. Oncol. 2014, 32, 2142–2150. [Google Scholar] [CrossRef] [PubMed]
- Tabar, L.; Fagerberg, G.; Day, N.E.; Duffy, S.W.; Kitchin, R.M. Breast cancer treatment and natural history: New insights from results of screening. Lancet 1992, 339, 412–414. [Google Scholar] [CrossRef]
- Hanrahan, E.O.; Gonzalez-Angulo, A.M.; Giordano, S.H.; Rouzier, R.; Broglio, K.R.; Hortobagyi, G.N.; Valero, V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J. Clin. Oncol. 2007, 25, 4952–4960. [Google Scholar] [CrossRef]
- Ho, A.Y.; Gupta, G.; King, T.A.; Perez, C.A.; Patil, S.M.; Rogers, K.H.; Wen, Y.H.; Brogi, E.; Morrow, M.; Hudis, C.A.; et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 2012, 118, 4944–4952. [Google Scholar] [CrossRef]
- Lee, H.Y.; Shin, I.S.; Rim, C.H. Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: A systematic review and meta-analysis. Ann. Transl. Med. 2020, 8, 187. [Google Scholar] [CrossRef]
- Cognetti, F.; Biganzoli, L.; De Placido, S.; Del Mastro, L.; Masetti, R.; Naso, G.; Pruneri, G.; Santini, D.; Tondini, C.A.; Tinterri, C.; et al. Multigene tests for breast cancer: The physician’s perspective. Oncotarget 2021, 12, 936–947. [Google Scholar] [CrossRef]
- Taylor, C.; McGale, P.; Probert, J.; Broggio, J.; Charman, J.; Darby, S.C.; Kerr, A.J.; Whelan, T.; Cutter, D.J.; Mannu, G.; et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: Population based observational cohort study. BMJ 2023, 381, e074684. [Google Scholar] [CrossRef]
- Veronesi, U.; Cascinelli, N.; Mariani, L.; Greco, M.; Saccozzi, R.; Luini, A.; Aguilar, M.; Marubini, E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 2002, 347, 1227–1232. [Google Scholar] [CrossRef]
- Metzger-Filho, O.; Sun, Z.; Viale, G.; Price, K.N.; Crivellari, D.; Snyder, R.D.; Gelber, R.D.; Castiglione-Gertsch, M.; Coates, A.S.; Goldhirsch, A.; et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX. J. Clin. Oncol. 2013, 31, 3083–3090. [Google Scholar] [CrossRef] [PubMed]
- Voduc, K.D.; Cheang, M.C.; Tyldesley, S.; Gelmon, K.; Nielsen, T.O.; Kennecke, H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 2010, 28, 1684–1691. [Google Scholar] [CrossRef] [PubMed]
- Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13, 4429–4434. [Google Scholar] [CrossRef] [PubMed]
- van ’t Veer, L.J.; Dai, H.; van de Vijver, M.J.; He, Y.D.; Hart, A.A.; Mao, M.; Peterse, H.L.; van der Kooy, K.; Marton, M.J.; Witteveen, A.T.; et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530–536. [Google Scholar] [CrossRef]
- Lowery, A.J.; Kell, M.R.; Glynn, R.W.; Kerin, M.J.; Sweeney, K.J. Locoregional recurrence after breast cancer surgery: A systematic review by receptor phenotype. Breast Cancer Res. Treat. 2012, 133, 831–841. [Google Scholar] [CrossRef]
- Tran, B.; Bedard, P.L. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011, 13, 221. [Google Scholar] [CrossRef]
- Wu, X.; Baig, A.; Kasymjanova, G.; Kafi, K.; Holcroft, C.; Mekouar, H.; Carbonneau, A.; Bahoric, B.; Sultanem, K.; Muanza, T. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus 2016, 8, e924. [Google Scholar] [CrossRef]
- van Maaren, M.C.; de Munck, L.; Strobbe, L.J.A.; Sonke, G.S.; Westenend, P.J.; Smidt, M.L.; Poortmans, P.M.P.; Siesling, S. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int. J. Cancer 2019, 144, 263–272. [Google Scholar] [CrossRef]
- Kim, J.; Hurria, A. Determining chemotherapy tolerance in older patients with cancer. J. Natl. Compr. Cancer Netw. 2013, 11, 1494–1502. [Google Scholar] [CrossRef]
- Ring, A.; Harder, H.; Langridge, C.; Ballinger, R.S.; Fallowfield, L.J. Adjuvant chemotherapy in elderly women with breast cancer (AChEW): An observational study identifying MDT perceptions and barriers to decision making. Ann. Oncol. 2013, 24, 1211–1219. [Google Scholar] [CrossRef]
- Yang, Z.; Chen, Y.; Liu, X.; Cui, J.; Hu, Y.; Wei, W. Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis. Cancer Treat. Res. Commun. 2020, 25, 100211. [Google Scholar] [CrossRef] [PubMed]
- Stravodimou, A.; Voutsadakis, I.A. Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: From chemotherapy to hormonal therapy, CDK inhibitors, and beyond. Expert Rev. Anticancer Ther. 2024, 24, 117–135. [Google Scholar] [CrossRef] [PubMed]
- Jones, S.E.; Collea, R.; Paul, D.; Sedlacek, S.; Favret, A.M.; Gore, I., Jr.; Lindquist, D.L.; Holmes, F.A.; Allison, M.A.K.; Brooks, B.D.; et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol. 2013, 14, 1121–1128. [Google Scholar] [CrossRef] [PubMed]
- Tolaney, S.M.; Barry, W.T.; Dang, C.T.; Yardley, D.A.; Moy, B.; Marcom, P.K.; Albain, K.S.; Rugo, H.S.; Ellis, M.; Shapira, I.; et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med. 2015, 372, 134–141. [Google Scholar] [CrossRef] [PubMed]
- Sharma, P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr. Treat. Options Oncol. 2018, 19, 22. [Google Scholar] [CrossRef]
- Blum, J.L.; Flynn, P.J.; Yothers, G.; Asmar, L.; Geyer, C.E., Jr.; Jacobs, S.A.; Robert, N.J.; Hopkins, J.O.; O’Shaughnessy, J.A.; Dang, C.T.; et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J. Clin. Oncol. 2017, 35, 2647–2655. [Google Scholar] [CrossRef]
- Hassing, C.M.S.; Mejdahl, M.K.; Laenkholm, A.V.; Kroman, N.; Knoop, A.S.; Tvedskov, T.H.F. Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors </= 10 mm: A nationwide study. Breast Cancer Res. Treat. 2022, 196, 197–206. [Google Scholar] [CrossRef]
- Shen, K.; Yao, L.; Zhu, J.; Gu, X.; Wang, J.; Qian, W.; Zheng, Z.; Fu, D.; Wu, S. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: A propensity score matching study based on SEER database and external cohort. BMC Cancer 2022, 22, 863. [Google Scholar] [CrossRef]
- Wu, C.; Huang, O.; Wu, J.; Shen, K.; Chen, X.; Zhu, S. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: A multicenter and propensity score matched analysis. Gland. Surg. 2023, 12, 1375–1386. [Google Scholar] [CrossRef]
- Kc, M.; Fan, J.; Hyslop, T.; Hassan, S.; Cecchini, M.; Wang, S.Y.; Silber, A.; Leapman, M.S.; Leeds, I.; Wheeler, S.B.; et al. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Netw. Open 2023, 6, e2323115. [Google Scholar] [CrossRef]
Women with Disease Recurrence (n = 30) | Women Remaining Disease-Free (n = 613) | p Value | |
---|---|---|---|
Median age (years) | 55 (40–77) | 58 (28–86) | 0.379 |
Menstrual status | 0.382 | ||
Pre-menopausal | 11 (36.7%) | 179 (29.2%) | |
Post-menopausal | 19 (63.3%) | 434 (70.8%) | |
Ethnicity | 0.839 | ||
Chinese | 27 (90.0%) | 538 (87.8%) | |
Malay | 2 (6.67%) | 36 (6.20%) | |
Indian | 1 (3.33%) | 23 (3.75%) | |
Others | 0 (0.00%) | 16 (2.61%) | |
Surgery | 0.029 | ||
Wide local excision | 20 (66.7%) | 284 (46.3%) | |
Mastectomy | 10 (33.3%) | 329 (53.7%) | |
T status | 0.649 | ||
T1mi | 2 (6.7%) | 25 (4.1%) | |
T1a | 6 (20.0%) | 71 (11.6%) | |
T1b | 1 (3.3%) | 93 (15.2%) | |
T1c | 21 (70.0%) | 245 (40.0%) | |
Median invasive size (mm) | 13 (0–20) | 12 (0–20) | 0.032 |
Median tumour size (mm) | 20 (3–60) | 16 (1–120) | 0.047 |
Subtypes * | 0.437 | ||
HR+/PR+/HER2- | 21 (70.0%) | 438 (71.5%) | |
HER2+ | 3 (10.0%) | 105 (17.1%) | |
ER-/PR-/HER2- | 6 (20.0%) | 70 (11.4%) | |
Chemotherapy | 0.380 | ||
Not received | 20 (66.7%) | 453 (73.9%) | |
Received | 10 (33.3%) | 160 (26.1%) | |
Hormonal therapy | 0.217 | ||
Not received | 11 (36.7%) | 162 (26.4%) | |
Received | 19 (63.3%) | 451 (73.6%) |
Variable | Level | Odds Ratio | p Value | 95% CI |
---|---|---|---|---|
Median tumour size | - | 1.019 | 0.063 | 0.999–1.040 |
Surgery | WLE alone WLE + RT Mastectomy | Reference 0.277 0.122 | Reference 0.022 0.001 | Reference 0.092–0.830 0.037–0.399 |
Women Recommended Chemotherapy +/− Targeted Therapy (n = 334) | Women Not Recommended Chemotherapy +/− Targeted Therapy (n = 309) | p Value | |
---|---|---|---|
Median age (years) | 57 (28–74) | 60 (31–86) | <0.001 |
Menstrual status | <0.001 | ||
Pre-menopausal | 118 (35.3%) | 72 (23.3%) | |
Post-menopausal | 216 (64.7%) | 237 (76.7%) | |
Ethnicity | 0.463 | ||
Chinese | 294 (88.0%) | 271 (87.7%) | |
Malay | 23 (6.9%) | 15 (4.9%) | |
Indian | 10 (3.0%) | 14 (4.5%) | |
Others | 7 (2.1%) | 9 (2.9%) | |
Surgery | 0.262 | ||
Wide local excision | 165 (49.4%) | 139 (45.0%) | |
Mastectomy | 169 (50.6%) | 170 (55.0%) | |
T status | <0.001 | ||
T1mi | 0 (0%) | 36 (11.7%) | |
T1a | 5 (1.5%) | 93 (30.1%) | |
T1b | 46 (13.5%) | 91 (29.4%) | |
T1c | 283 (84.7%) | 89 (28.8%) | |
Median invasive size (mm) | 15 (1–20) | 7 (1–20) | <0.001 |
Subtypes * | <0.001 | ||
HR+/HER2- | 198 (59.3%) | 261 (84.5%) | |
HER2+ | 89 (26.6%) | 19 (6.1%) | |
ER-/PR-/HER2- | 47 (14.1%) | 29 (9.4%) |
Women Treated with Chemotherapy With/Without Targeted Therapy (n = 169) | Women with No Chemotherapy or Targeted Therapy (n = 165) | p Value | |
---|---|---|---|
Median age (years) | 55 (28–84) | 60 (35–83) | <0.001 |
Menstrual status | 0.095 | ||
Pre-menopausal | 67 (39.6%) | 51 (30.9%) | |
Post-menopausal | 102 (60.4%) | 114 (69.1%) | |
Ethnicity | 0.651 | ||
Chinese | 145 (85.7%) | 149 (90.3%) | |
Malay | 14 (8.2%) | 9 (5.5%) | |
Indian | 6 (3.6%) | 4 (2.4%) | |
Others | 4 (2.4%) | 3 (1.8%) | |
Surgery | 0.230 | ||
Wide local excision | 78 (46.2%) | 87 (52.7%) | |
Mastectomy | 91 (53.8%) | 78 (47.3%) | |
T status | 0.736 | ||
T1mi | 0 (0.0%) | 0 (0.0%) | |
T1a | 3 (1.8%) | 2 (1.2%) | |
T1b | 20 (11.8%) | 26 (15.8%) | |
T1c | 146 (86.4%) | 137 (83.0%) | |
Subtypes * | <0.001 | ||
HR+/HER2- | 65 (38.5%) | 133 (80.6%) | |
HER2+ | 71 (42.0%) | 18 (10.9%) | |
ER-/PR-/HER2- | 33 (19.5%) | 14 (8.5%) | |
Disease recurrence | 0.578 | ||
Isolated locoregional recurrence | 8 (4.7%) | 2 (1.2%) | |
Systemic recurrence | 3 (1.8%) | 3 (1.8%) | |
No recurrence | 158 (93.5%) | 160 (97.0%) | |
Contralateral breast cancer | |||
Yes | 7 (4.1%) | 4 (2.4%) | |
No | 162 (95.6%) | 161 (97.6%) | |
Death | 0.379 | ||
Breast-specific | 0 (0.0%) | 1 (0.6%) | |
Other causes | 0 (0.0%) | 3 (1.8%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chan, P.M.Y.; Ong, K.H.; Kuah, S.; Sim, E.J.; Chen, J.; Goh, M.H.; Ang, W.-W.; Tan, E.Y. Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers. Cancers 2024, 16, 4228. https://doi.org/10.3390/cancers16244228
Chan PMY, Ong KH, Kuah S, Sim EJ, Chen J, Goh MH, Ang W-W, Tan EY. Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers. Cancers. 2024; 16(24):4228. https://doi.org/10.3390/cancers16244228
Chicago/Turabian StyleChan, Patrick Mun Yew, Kay Hsiang Ong, Sherwin Kuah, E Jan Sim, Juliana Chen, Mui Heng Goh, Wei-Wen Ang, and Ern Yu Tan. 2024. "Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers" Cancers 16, no. 24: 4228. https://doi.org/10.3390/cancers16244228
APA StyleChan, P. M. Y., Ong, K. H., Kuah, S., Sim, E. J., Chen, J., Goh, M. H., Ang, W.-W., & Tan, E. Y. (2024). Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers. Cancers, 16(24), 4228. https://doi.org/10.3390/cancers16244228